关于龙沙<\/p> \n
龙沙是全球制药、生物技术与营养市场的优秀合作伙伴。 我们致力于助力客户推出创新药物辅助治疗一系列的疾病，成就更健康的世界。为达成这一使命，我们将先进生产制造、科学专业技术、卓越工艺及技术洞察力完美结合。我们全方位的产品与服务帮助客户在医疗保健领域的发现与创新成果实现商业化。<\/p> \n
1897年，龙沙诞生于瑞士的阿尔卑斯山脉地区。发展至今，业务已遍及全球五大洲。 我们拥有约15,000名员工，由他们组成的高效团队及每一名员工都为我们的业务和所在地区及国家做出意义非凡的改变。2021年上半年，公司销售额达25亿瑞士法郎，核心业务的息税折旧摊销前利润（EBITDA）达8.47亿瑞士法郎。更多详情，请访问 www.lonza.com<\/a>。<\/p> \n 关于道尔生物<\/p> \n 浙江道尔生物科技有限公司成立于2014年04月01日，为华东医药（股票代码：SZ 000963）控股的专业从事创新生物药开发的高科技企业，研发中心位于杭州医药港小镇。公司聚焦于开发基于多结构域的多特异性创新蛋白药物，以满足代谢疾病、癌症、眼科等领域的未被满足的临床需求。于2018年被评审为国家高新技术企业，2021年度入选杭州市准独角兽企业。<\/p> \n 道尔生物拥有xLONGylation®<\/sup> --重组类PEG化修饰（rPEG）蛋白长效化改造平台技术，MultipleBody®<\/sup> -- 多靶点技术平台，SMART-VHHBody-单域抗体一站式高通量发现和改造平台，以及AccuBody®<\/sup> -- 肿瘤精准治疗技术平台等多个独创的蛋白工程平台技术。基于这些技术平台，公司开发了多个创新的基于多结构域的多特异性蛋白药物，数个项目已申报临床。更多详情，请访问：www.doerbio.com<\/a> <\/p> \n Additional Information and Disclaimer<\/b><\/p> \n Lonza Group Ltd has its headquarters in Basel, Switzerland<\/span>, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.<\/p> \n Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.<\/p>"];
$("#dvExtra").html(content_array[0]);})();